Your session is about to expire
← Back to Search
Stem Cell Therapy
treatment with A3 SVF for Osteoarthritis
N/A
Waitlist Available
Led By John Huh, MD
Research Sponsored by Institute of Regenerative and Cellular Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
Study Summary
To purpose of this study is to determine if treatment with SVF (Stromal Vascular Fraction) has an effect on pain and inflammation associated with Osteoarthritis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain and Inflammation - WOMAC scores, comprehensive inflammation blood panel
Secondary outcome measures
Pain and Mobility Assessment
Trial Design
1Treatment groups
Experimental Treatment
Group I: treatment with A3 SVFExperimental Treatment1 Intervention
These patients that have been treated. The control patients that have not been treated.
Find a Location
Who is running the clinical trial?
Institute of Regenerative and Cellular MedicineLead Sponsor
Barbara KrutchkoffStudy ChairInstitute of Regenerative and Cellular Medicine
John Huh, MDPrincipal InvestigatorICMS
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger